0001387131-20-010040.txt : 20201116 0001387131-20-010040.hdr.sgml : 20201116 20201116172343 ACCESSION NUMBER: 0001387131-20-010040 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20201116 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201116 DATE AS OF CHANGE: 20201116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36242 FILM NUMBER: 201318478 BUSINESS ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 997-2400 MAIL ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 8-K 1 admp-8k_111620.htm CURRENT REPORT
0000887247 false 0000887247 2020-11-16 2020-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 16, 2020

 

 

ADAMIS PHARMACEUTICALS CORPORATION

(Exact Name of Registrant as Specified in Charter)

 

Delaware   0-26372   82-0429727

(State or other jurisdiction

of incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

         

11682 El Camino Real, Suite 300

San Diego, CA

   92130
(Address of Principal Executive Offices)   (Zip Code)
             

 

Registrant’s telephone number, including area code: (858) 997-2400

(Former name or Former Address, if Changed Since Last Report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   ADMP   NASDAQ
Capital Market

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

 

Item 8.01Other Events

On November 16, 2020, Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) issued a press release announcing that after the close of U.S. markets on November 13, 2020, it received a Complete Response Letter (“CRL”) from the U.S. Food & Drug Administration (“FDA”) regarding the Company’s resubmitted New Drug Application (“NDA”) for its ZIMHI™ high-dose naloxone injection product for the treatment of opioid overdose. A CRL is issued by the FDA's Center for Drug Evaluation and Research when it has completed its review of a file and questions remain that preclude the approval of the NDA in its current form. The CRL stated that the FDA determined that it cannot approve the Company’s NDA in its present form and provided recommendations needed for resubmission. The questions raised by the FDA related generally to new Chemistry, Manufacturing and Controls (CMC) issues. The Company is reviewing the CRL, plans to provide the FDA with additional analysis and information in order to attempt to satisfy the CRL items, and intends to request a Type A meeting or consider other options to resolve the issues.

A copy of the Company’s press release is attached hereto as Exhibit 99.1 is incorporated into this item by reference.

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to the following statements: the company’s beliefs concerning its ability to satisfactorily respond to the matters raised in the FDA’s CRL; the company’s beliefs concerning the information, data and actions that the FDA may require in connection with any resubmitted NDA relating to ZIMHI; the company’s beliefs concerning the results of any future studies or clinical trials that the company may conduct relating to ZIMHI or its other products or product candidates; the company’s beliefs concerning the timing and outcome of the FDA’s review of the company’s NDA relating to the ZIMHI product or any resubmitted NDA; the company’s beliefs concerning its ability to commercialize ZIMHI and its other products and product candidates; the company's beliefs concerning the ability of its product candidates to compete successfully in the market; the company's beliefs concerning the safety and effectiveness of ZIMHI; the company’s beliefs concerning its commercialization strategies; and the company’s beliefs concerning the anticipated timing of any commercial launch of its ZIMHI product. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis' actual results to be materially different from these forward-looking statements. The FDA may require additional studies, and/or other actions, data or information, prior to any resubmission of the NDA. There can be no assurances that the company will be able to satisfactorily respond to the matters raised in the FDA’s CRL or concerning the timing of any resubmission by us of the NDA responding to the CRL, concerning the timing or costs of any additional actions that may be required in connection with any resubmission of the NDA, that the FDA will approve any resubmitted NDA relating to our ZIMHI product or concerning the timing of any future action by the FDA on our NDA, or that the product will be able to compete successfully in the market if approved and launched. In addition, forward-looking statements concerning our anticipated future activities assume that we are able to obtain sufficient funding to support such activities and continue our operations and planned activities. As discussed in our filings with the Securities and Exchange Commission, we will require additional funding, and there are no assurances that such funding will be available if required. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Except to the extent required by law, any forward-looking statements in this Report speak only as the date of this Report, and Adamis expressly disclaims any obligation to update any forward-looking statements.

 

Item 9.01Financial Statements and Exhibits

 

(d) Exhibits.

 

99.1       Press release dated November 16, 2020.

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  ADAMIS PHARMACEUTICALS CORPORATION
     
     
Dated: November 16, 2020 By: /s/ Robert O. Hopkins
  Name: Robert O. Hopkins
  Title: Chief Financial Officer

 

 

 

 

 

 

 

 EX-99.1 2 ex99-1.htm PRESS RELEASE

 

Adamis Pharmaceuticals Corp. 8-K

Exhibit 99.1

 

 

Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI

 

SAN DIEGO--(November 16, 2020)- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of business and the U.S. markets on November 13th, it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Adamis’ ZIMHI™ high dose naloxone injection product for the treatment of opioid overdose. The CRL stated that the FDA determined it cannot approve the NDA in its present form and provided recommendations needed for resubmission.

 

A CRL is issued by the FDA's Center for Drug Evaluation and Research when it has completed its review of a file and questions remain that preclude the approval of the NDA in its current form. The questions raised by the FDA related generally to new Chemistry, Manufacturing and Controls (CMC) issues. It should be noted that no issues related to “extractables and leechables testing”, that were associated with the previous initial CRL that the company received relating to the product, were noted by the FDA. The company’s plan is to provide the FDA with additional analysis and information in order to attempt to satisfy the CRL items. The company will request a Type A meeting or consider other options to resolve the issues.

 

Dr. Dennis J. Carlo, President and CEO of Adamis, stated, “This is a very disappointing setback that was totally unexpected since we completed the extractables and leechables issues that were associated with the first CRL. To me, it is very surprising to have new issues brought up this late in the review process. We believe the comments and recommendations stated in the CRL can be addressed and overcome. With all of the factors that are currently contributing to a growing number of fatal overdoses during the COVID-19 pandemic, we believe there is a clear need for higher dose forms of intramuscular naloxone found in ZIMHI. We remain committed to this product and our mission to provide physicians and patients access to a higher dose of naloxone. As soon as reasonably possible, we will resubmit additional information and analysis of data to the FDA for the NDA.”

 

About ZIMHI

ZIMHI is a high-dose naloxone injection product candidate intended for the treatment of opioid overdose. Naloxone is an opioid antagonist and is generally considered the drug of choice for immediate administration for opioid overdose. It works by blocking or reversing the effects of the opioid, including extreme drowsiness, slowed breathing, or loss of consciousness. Common opioids include morphine, heroin, tramadol, oxycodone, hydrocodone and fentanyl. According to statistics published by the Centers for Disease Control and Prevention (CDC) in 2018, drug overdoses resulted in approximately 67,000 deaths in the United States – greater than 185 deaths per day. Drug overdoses are now the leading cause of death for Americans under 50, and more powerful synthetic opioids, like fentanyl and its analogues, are responsible for the largest number of deaths from opioid overdoses.

 

 

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company’s SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. In addition to its ZIMHI, naloxone injection product candidate, Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma and COPD. The company’s subsidiary, U.S. Compounding, Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States.

 

Adamis Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to the following statements: the company’s beliefs concerning its ability to satisfactorily respond to the matters raised in the FDA’s CRL; the company’s beliefs concerning the information, data and actions that the FDA may require in connection with any resubmitted NDA relating to ZIMHI; the company’s beliefs concerning the results of any future studies or clinical trials that the company may conduct relating to ZIMHI or its other products or product candidates; the company’s beliefs concerning the timing and outcome of the FDA’s review of the company’s New Drug Application (NDA) relating to the ZIMHI product or any resubmitted NDA; the company’s beliefs concerning its ability to commercialize ZIMHI and its other products and product candidates; the company's beliefs concerning the ability of its product candidates to compete successfully in the market; the company's beliefs concerning the safety and effectiveness of ZIMHI or its other products and product candidates; the company’s beliefs concerning its commercialization strategies; and the company’s beliefs concerning the anticipated timing of any commercial launch of its ZIMHI product. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis' actual results to be materially different from these forward-looking statements. The FDA may require additional studies, and/or other actions, data or information, prior to any resubmission of the NDA. There can be no assurances that the company will be able to satisfactorily respond to the matters raised in the FDA’s CRL or concerning the timing of any resubmission by us of the NDA responding to the CRL, concerning the timing or costs of any additional actions that may be required in connection with any resubmission of the NDA, that the FDA will approve any resubmitted NDA relating to our ZIMHI product or concerning the timing of any future action by the FDA on our NDA, or that the product will be able to compete successfully in the market if approved and launched. In addition, forward-looking statements concerning our anticipated future activities assume that we are able to obtain sufficient funding to support such activities and continue our operations and planned activities. As discussed in our filings with the Securities and Exchange Commission, we will require additional funding, and there are no assurances that such funding will be available if required. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Except to the extent required by law, any forward-looking statements in this press release speak only as the date of this press release, and Adamis expressly disclaims any obligation to update any forward-looking statements.

 

Contact Adamis:

Mark Flather

Senior Director, Investor Relations & Corporate Communications (858) 412-7951

mflather@adamispharma.com

 

 

 

 

 EX-101.SCH 3 admp-20201116.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 admp-20201116_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 admp-20201116_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 admp-8k_111620_htm.xml IDEA: XBRL DOCUMENT 0000887247 2020-11-16 2020-11-16 iso4217:USD shares iso4217:USD shares 0000887247 false 8-K 2020-11-16 ADAMIS PHARMACEUTICALS CORPORATION DE 0-26372 82-0429727 11682 El Camino Real Suite 300 San Diego CA 92130 (858) 997-2400 false false false false Common Stock ADMP NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Nov. 16, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 16, 2020
Entity File Number 0-26372
Entity Registrant Name ADAMIS PHARMACEUTICALS CORPORATION
Entity Central Index Key 0000887247
Entity Tax Identification Number 82-0429727
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 11682 El Camino Real
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code (858)
Local Phone Number 997-2400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ADMP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://adamispharmaceuticals.com/role/Cover Cover Cover 1 false false All Reports Book All Reports admp-8k_111620.htm admp-20201116.xsd admp-20201116_lab.xml admp-20201116_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "admp-8k_111620.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "admp-8k_111620.htm" ] }, "labelLink": { "local": [ "admp-20201116_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "admp-20201116_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "admp-20201116.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ADMP", "nsuri": "http://adamispharmaceuticals.com/20201116", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "admp-8k_111620.htm", "contextRef": "From2020-11-16to2020-11-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://adamispharmaceuticals.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "admp-8k_111620.htm", "contextRef": "From2020-11-16to2020-11-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001387131-20-010040-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-20-010040-xbrl.zip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